RxDoctor Payments Data

Eric Levine, MD

Cardiovascular Disease · Dartmouth, MANPI 1528038734

Payments from drug & device makers

$2,487in general payments, 2019–2025

Across 104 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$406
  • Novartis$323
  • Boehringer Ingelheim$222
  • AstraZeneca$182
  • E.r. Squibb & Sons, L.L.C.$178
  • Kiniksa Pharmaceuticals International, PLC$148
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,487 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$372,886
Medicare patients
1,058
Services billed
5,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban514$622,348
JardianceEmpagliflozin175$233,793
XareltoRivaroxaban151$186,097
FarxigaDapagliflozin Propanediol25$39,782
EntrestoSacubitril/Valsartan14$25,946
BrilintaTicagrelor15$14,926
Metoprolol Succinate639$14,024
Atorvastatin Calcium860$13,132
Repatha SureclickEvolocumab15$8,103
Rosuvastatin Calcium227$7,819
Ezetimibe152$7,705
Isosorbide Mononitrate ErIsosorbide Mononitrate191$4,073
Dabigatran EtexilateDabigatran Etexilate Mesylate26$3,948
ClopidogrelClopidogrel Bisulfate200$3,552
Losartan Potassium215$3,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$406$622,348514 claims
Boehringer IngelheimJardiance$222$233,793175 claims
Johnson & JohnsonXarelto$50$186,097151 claims
AstraZenecaFarxiga, Brilinta$182$54,70840 claims
NovartisEntresto$323$25,94614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Dartmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →